{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:11:28Z","timestamp":1780089088389,"version":"3.54.0"},"publisher-location":"Berlin, Heidelberg","reference-count":114,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642056437","type":"print"},{"value":"9783662088852","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004]]},"DOI":"10.1007\/978-3-662-08885-2_3","type":"book-chapter","created":{"date-parts":[[2013,7,8]],"date-time":"2013-07-08T10:08:04Z","timestamp":1373278084000},"page":"53-109","source":"Crossref","is-referenced-by-count":3,"title":["Multiple Myeloma"],"prefix":"10.1007","author":[{"given":"Angela","family":"Dispenzieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip R.","family":"Greipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"3_CR1","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/S0140-6736(76)92710-0","volume":"1","author":"DS Alberts","year":"1976","unstructured":"Alberts DS, Durie BG, Salmon SE (1976) Doxorubicin\/B.C.N.U. chemotherapy for multiple myeloma in relapse. Lancet 1:926\u2013928","journal-title":"Lancet"},{"key":"3_CR2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood.V56.3.521.521","volume":"56","author":"R Alexanian","year":"1980","unstructured":"Alexanian R (1980) Localized and indolent myeloma. Blood 56:521\u2013525","journal-title":"Blood"},{"key":"3_CR3","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1002\/1097-0142(197712)40:6<2765::AID-CNCR2820400602>3.0.CO;2-X","volume":"40","author":"R Alexanian","year":"1977","unstructured":"Alexanian R, Salmon S, Bonnet J, Gehan E, Haut A, Weick J (1977) Combination therapy for multiple myeloma. Cancer 40:2765\u20132771","journal-title":"Cancer"},{"key":"3_CR4","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood.V51.6.1005.1005","volume":"51","author":"R Alexanian","year":"1978","unstructured":"Alexanian R, Gehan E, Haut A, Saiki J, Weick J (1978) Unmaintained remissions in multiple myeloma. Blood 51:1005\u20131011","journal-title":"Blood"},{"key":"3_CR5","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/ajh.2830330203","volume":"33","author":"R Alexanian","year":"1990","unstructured":"Alexanian R, Barlogie B, Tucker S (1990) VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 33:86\u201389","journal-title":"Am J Hematol"},{"key":"3_CR6","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood.V80.4.887.887","volume":"80","author":"R Alexanian","year":"1992","unstructured":"Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B (1992) Primary dexamethasone treatment of multiple myeloma. Blood 80:887\u2013890","journal-title":"Blood"},{"key":"3_CR7","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/1096-8652(200011)65:3<204::AID-AJH5>3.0.CO;2-H","volume":"65","author":"R Alexanian","year":"2000","unstructured":"Alexanian R, Weber D, Dimopoulos M, Delasalle K, Smith TL (2000) Randomized trial of alpha-interferon or dexamethasone as maintenance treatment for multiple myeloma. Am J Hematol 65:204\u2013209","journal-title":"Am J Hematol"},{"key":"3_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome. N Engl J Med 335:91\u201397","journal-title":"N Engl J Med"},{"key":"3_CR9","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1182\/blood.V99.6.2185","volume":"99","author":"H Avet-Loiseau","year":"2002","unstructured":"Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL, Minvielle S, Bataille R, for the Intergroupe Francophone du My\u00e9lome (2002) Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 99:2185\u20132191","journal-title":"Blood"},{"key":"3_CR10","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1200\/JCO.20.5.1295","volume":"20","author":"A Badros","year":"2002","unstructured":"Badros A, Barlogie B, Siegel E, Cotter-Fox M, Zangari M, Fassas A, Morris C, Anaissie E, Van Rhee F, Tricot G (2002) Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 20:1295\u20131303","journal-title":"J Clin Oncol"},{"key":"3_CR11","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJM198405243102104","volume":"310","author":"B Barlogie","year":"1984","unstructured":"Barlogie B, Smith L, Alexanian R (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310:1353\u20131356","journal-title":"N Engl J Med"},{"key":"3_CR12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/hon.2900060217","volume":"6","author":"B Barlogie","year":"1988","unstructured":"Barlogie B, Dicke KA, Alexanian R (1988) High dose melphalan for refractory myeloma: the M.D. Anderson experience. Hematol Oncol 6:167\u2013172","journal-title":"Hematol Oncol"},{"key":"3_CR13","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1200\/JCO.1989.7.10.1514","volume":"7","author":"B Barlogie","year":"1989","unstructured":"Barlogie B, Velasquez WS, Alexanian R, Cabanillas F (1989) Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma. J Clin Oncol 7:1514\u20131517","journal-title":"J Clin Oncol"},{"key":"3_CR14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","volume":"93","author":"B Barlogie","year":"1999","unstructured":"Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J (1999) Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93:55\u201365","journal-title":"Blood"},{"key":"3_CR15","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/ajcp\/87.3.342","volume":"87","author":"R Bartl","year":"1987","unstructured":"Bartl R, Frisch B, Fateh-Moghadam A, Kettner G, Jaeger K, Sommerfeld W (1987) Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol 87:342\u2013355","journal-title":"Am J Clin Pathol"},{"key":"3_CR16","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJM199706053362307","volume":"336","author":"R Bataille","year":"1997","unstructured":"Bataille R, Harousseau JL (1997) Multiple myeloma. N Engl J Med 336:1657\u20131664","journal-title":"N Engl J Med"},{"key":"3_CR17","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.V80.3.733.733","volume":"80","author":"R Bataille","year":"1992","unstructured":"Bataille R, Boccadoro M, Klein B, Durie B, Pileri A (1992) C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 80:733\u2013737","journal-title":"Blood"},{"key":"3_CR18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/bjc.1988.17","volume":"57","author":"A Belch","year":"1988","unstructured":"Belch A, Shelley W, Bergsagel D, Wilson K, Klimo P, White D, Willan A (1988) A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 57:94\u201399","journal-title":"Br J Cancer"},{"key":"3_CR19","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1182\/blood.V88.7.2787.bloodjournal8872787","volume":"88","author":"W Bensinger","year":"1996","unstructured":"Bensinger Wl, Buckner CD, Anasetti C, Clift R, Storb R, Barnett T, Chauncey T, Shulman H, Appelbaum FR (1996) Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 88:2787\u20132793","journal-title":"Blood"},{"key":"3_CR20","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","volume":"16","author":"JR Berenson","year":"1998","unstructured":"Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J, Knight RD (1998) Long-term Pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16:593\u2013602","journal-title":"J Clin Oncol"},{"key":"3_CR21","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1182\/blood.V99.9.3163","volume":"99","author":"JR Berenson","year":"2002","unstructured":"Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM, Barlogie B, Salmon SE (2002) Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 99:3163\u20133168","journal-title":"Blood"},{"key":"3_CR22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0065-230X(08)60081-0","volume":"10","author":"DE Bergsagel","year":"1967","unstructured":"Bergsagel DE, Griffith KM, Haut A, Stuckey WJ Jr (1967) The treatment of plasma cell myeloma. Adv Cancer Res 10:311\u2013359","journal-title":"Adv Cancer Res"},{"key":"3_CR23","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/sj.bmt.1702826","volume":"27","author":"B Bjorkstrand","year":"2001","unstructured":"Bjorkstrand B, Svensson H, Goldschmidt H, Ljungman P, Apperley J, Mandelli F, Marcus R, Boogaerts M, Alegre A, Remes K, Cornelissen JJ, Blad\u00e9 J, Lenhoff S, Iriondo A, Carlson K, Volin L, Littlewood T, Goldstone AH, San Miguel J, Schattenberg A, Gahrton G (2001) Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 27:511\u2013515","journal-title":"Bone Marrow Transplant"},{"key":"3_CR24","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1182\/blood.V88.12.4711.bloodjournal88124711","volume":"88","author":"BB Bjorkstrand","year":"1996","unstructured":"Bjorkstrand BB, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J, Blad\u00e9 J, Carlson K, Cavo M, Ferrant A, Goldstone AH, de Laurenzi A, Majolino I, Marcus R, Prentice HG, Remes K, Samson D, Sureda A, Verdonck LF, Volin L, Gahrton G (1996) Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 88:4711\u20134718","journal-title":"Blood"},{"key":"3_CR25","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0889-8588(05)70125-8","volume":"13","author":"J Blad\u00e9","year":"1999","unstructured":"Blad\u00e9 J, Kyle RA (1999) Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am 13:1259\u20131272","journal-title":"Hematol Oncol Clin North Am"},{"key":"3_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1365-2141.1994.tb04986.x","volume":"88","author":"J Blad\u00e9","year":"1994","unstructured":"Blad\u00e9 J, Lopez-Guillermo A, Bosch F, Cervantes F, Reverter JC, Montserrat E, Rozman C (1994) Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. Br J Haematol 88:117\u2013121","journal-title":"Br J Haematol"},{"key":"3_CR27","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blad\u00e9","year":"1998","unstructured":"Blad\u00e9 J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102:1115\u20131123","journal-title":"Br J Haematol"},{"key":"3_CR28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1200\/JCO.1989.7.1.119","volume":"7","author":"M Boccadoro","year":"1989","unstructured":"Boccadoro M, Marmont F, Tribalto M, Fossati G, Redoglia V, Battaglio S, Massaia M, Gallamini A, Comotti B, Barbui T, Campobasso N, Dammacco F, Cantonetti M, Petrucci MT, Mandelli F, Resegotti L, Pileri A (1989) Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis. J Clin Oncol 7:119\u2013125","journal-title":"J Clin Oncol"},{"key":"3_CR29","first-page":"1267","volume":"66","author":"J Bonnet","year":"1982","unstructured":"Bonnet J, Alexanian R, Salmon S, Bottomley R, Amare M, Haut A, Dixon D (1982) Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study. Cancer Treat Rep 66:1267\u20131271","journal-title":"Cancer Treat Rep"},{"key":"3_CR30","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/0002-9343(77)90543-5","volume":"63","author":"DC Case Jr","year":"1977","unstructured":"Case DC Jr, Lee DJ III, Clarkson BD (1977) Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. Am J Med 63:897\u2013903","journal-title":"Am J Med"},{"key":"3_CR31","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1200\/JCO.1986.4.6.888","volume":"4","author":"HJ Cohen","year":"1986","unstructured":"Cohen HJ, Bartolucci AA, Forman WB, Silberman HR (1986) Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment. J Clin Oncol 4:888\u2013899","journal-title":"J Clin Oncol"},{"key":"3_CR32","first-page":"141","volume":"3","author":"Committee of the Chronic Leukemia-Myeloma Task Force NCI","year":"1973","unstructured":"Committee of the Chronic Leukemia-Myeloma Task Force NCI (1973) Proposed guidelines for protocol studies. I. Introduction. II. Plasma cell myeloma. III. Chronic lymphocytic leukemia. IV. Chronic granulocytic leukemia. Cancer Chemother Rep 3 vol 4:141\u2013173","journal-title":"Cancer Chemother Rep"},{"key":"3_CR33","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.1986.4.9.1331","volume":"4","author":"MR Cooper","year":"1986","unstructured":"Cooper MR, McIntyre OR, Propert KJ, Kochwa S, Anderson K, Coleman M, Kyle RA, Prager D, Rafla S, Zimmer B (1986) Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study. J Clin Oncol 4:1331\u20131339","journal-title":"J Clin Oncol"},{"key":"3_CR34","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1200\/JCO.1988.6.9.1481","volume":"6","author":"GG Cornwell","year":"1988","unstructured":"Cornwell GG III, Pajak TF, Kochwa S, Mclntyre OR, Glowienka LP, Brunner K, Rafla S, Coleman M, Cooper MR, Henderson E, Kyle RA, Haurani Fl, Cuttner J, Prager D, Holland JF (1988) Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma: Cancer and Leukemia Group B experience. J Clin Oncol 6:1481\u20131490","journal-title":"J Clin Oncol"},{"key":"3_CR35","first-page":"336","volume":"84","author":"A Corso","year":"1999","unstructured":"Corso A, Nozza A, Lazzarino M, Klersy C, Zappasodi P, Arcaini L, Bernasconi C (1999) Plateau phase in multiple myeloma: an end-point of conventional-dose chemotherapy. Haematologica 84:336\u2013341","journal-title":"Haematologica"},{"key":"3_CR36","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0037-1963(01)90011-3","volume":"38","author":"J Crowley","year":"2001","unstructured":"Crowley J, Jacobson J, Alexanian R (2001) Standard-dose therapy for multiple myeloma: the Southwest Oncology Group experience. Semin Hematol 38:203\u2013208","journal-title":"Semin Hematol"},{"key":"3_CR37","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1046\/j.1365-2141.1998.00795.x","volume":"102","author":"D Cunningham","year":"1998","unstructured":"Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C, Montes A, Hickish T, Nicolson M, Johnson P, Treleaven J, Raymond J, Gore M (1998) A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 102:495\u2013502","journal-title":"Br J Haematol"},{"key":"3_CR38","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/bjc.1987.107","volume":"55","author":"J Cuzick","year":"1987","unstructured":"Cuzick J, Erskine S, Edelman D, Galton DA (1987) A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council\u2019s Working Party on Leukaemia in Adults. Br J Cancer 55:523\u2013529","journal-title":"Br J Cancer"},{"key":"3_CR39","first-page":"157","volume-title":"Multiple myeloma","author":"WS Dalton","year":"2001","unstructured":"Dalton WS, Bergsagel PL, Kuehl WM, Anderson KC, Harousseau JL (2001) Multiple myeloma. Hematology (Am Soc Hematol Educ Program), pp 157\u2013177"},{"key":"3_CR40","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1046\/j.1365-2141.2001.02530.x","volume":"112","author":"FE Davies","year":"2001","unstructured":"Davies FE, Forsyth PD, Rawstron AC, Owen RG, Pratt G, Evans PA, Richards SJ, Drayson M, Smith GM, Selby PJ, Child JA, Morgan GJ (2001) The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol 112:814\u2013819","journal-title":"Br J Haematol"},{"key":"3_CR41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0300-2977(01)00140-1","volume":"59","author":"O Weerdt de","year":"2001","unstructured":"de Weerdt O, van de Donk NW, Veth G, Bloem AC, Hagenbeek A, Lokhorst HM (2001) Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma. Neth J Med 59:50\u201356","journal-title":"Neth J Med"},{"key":"3_CR42","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1023\/A:1011132808904","volume":"12","author":"MA Dimopoulos","year":"2001","unstructured":"Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C, Vervessou E, Samantas E, Papadimitriou C, Economou O, Gika D, Panayiotidis P, Christakis I, Anagnostopoulos N (2001) Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 12:991\u2013995","journal-title":"Ann Oncol"},{"key":"3_CR43","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1182\/blood-2002-07-2299","volume":"101","author":"A Dispenzieri","year":"2003","unstructured":"Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Therneau TM, Larson DR, Greipp PR, Witzig TE, Basu R, Suarez GA, Fonseca R, Lust JA, Gertz MA (2003) POEMS syndrome: definitions and long-term outcome. Blood 101:2496\u20132506","journal-title":"Blood"},{"key":"3_CR44","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1182\/blood.V97.9.2900","volume":"97","author":"M Drayson","year":"2001","unstructured":"Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR (2001) Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 97:2900\u20132902","journal-title":"Blood"},{"key":"3_CR45","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842\u2013854","journal-title":"Cancer"},{"key":"3_CR46","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/ajh.2830480201","volume":"48","author":"T Facon","year":"1995","unstructured":"Facon T, Menard JF, Michaux JL, Euller-Ziegler L, Bernard JF, Grosbois B, Daragon A, Azais I, Courouble Y, Kaplan G, LaPorte JP, De Gramont A, Duclos B, Leonard A, Mineur P, Delannoy A, Jouet JP, Bauters F, Monconduit M (1995) Prognostic factors in low tumour mass asymptomatic multiple myeloma: a report on 91 patients. The Groupe d\u2019Etudes et de Recherche sur le Myelome (GERM). Am J Hematol 48:71\u201375","journal-title":"Am J Hematol"},{"key":"3_CR47","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1182\/blood.V97.6.1566","volume":"97","author":"T Facon","year":"2001","unstructured":"Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M, Lai JL, Leleu X, Jouet JP, Bauters F, Harousseau JL, Bataille R, Mary JY (2001) Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 97:1566\u20131571","journal-title":"Blood"},{"key":"3_CR48","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","volume":"92","author":"JP Fermand","year":"1998","unstructured":"Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, Macro M, Pertuiset E, Dreyfus F, Mariette X, Boccacio C, Brouet JC (1998) High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92:3131\u20133136","journal-title":"Blood"},{"key":"3_CR49","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1046\/j.1365-2141.1999.01462.x","volume":"105","author":"Finnish Leukaemia Group","year":"1999","unstructured":"Finnish Leukaemia Group (1999) Long-term survival in multiple myeloma: a Finnish Leukaemia Group study. Br J Haematol 105:942\u2013947","journal-title":"Br J Haematol"},{"key":"3_CR50","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","volume":"101","author":"R Fonseca","year":"2003","unstructured":"Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, Dewald GW, Van Ness B, Van Wier SA, Henderson KJ, Bailey RJ, Greipp PR (2003) Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101:4569 \u2013 4575","journal-title":"Blood"},{"key":"3_CR51","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/bjc.1988.243","volume":"58","author":"GV Forgeson","year":"1988","unstructured":"Forgeson GV, Selby P, Lakhani S, Zulian G, Viner C, Maitland J, McElwain TJ (1988) Infused vincristine and Adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients. Br J Cancer 58:469\u2013473","journal-title":"Br J Cancer"},{"key":"3_CR52","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1056\/NEJM199110313251802","volume":"325","author":"G Gahrton","year":"1991","unstructured":"Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M, Facon T, Granena A, Gore M, Gratwohl A, L\u00f6wenberg B, Nikoskelainen J, Reiffers JJ, Samson D, Verdonck L, Volin L (1991) Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med 325:1267\u20131273","journal-title":"N Engl J Med"},{"key":"3_CR53","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1001\/archinte.1995.00430190059008","volume":"155","author":"JP Garton","year":"1995","unstructured":"Garton JP, Gertz MA, Witzig TE, Greipp PR, Lust JA, Schroeder G, Kyle RA (1995) Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial. Arch Intern Med 155:2069\u20132074","journal-title":"Arch Intern Med"},{"key":"3_CR54","first-page":"2115","volume":"9","author":"MA Gertz","year":"1995","unstructured":"Gertz MA, Garton JP, Greipp PR, Witzig TE, Kyle RA (1995) A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. Leukemia 9:2115\u20132118","journal-title":"Leukemia"},{"key":"3_CR55","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/archsurg.1928.01140040002001","volume":"16","author":"CF Geschickter","year":"1928","unstructured":"Geschickter CF, Copeland MM (1928) Multiple myeloma. Arch Surg 16:807\u2013863","journal-title":"Arch Surg"},{"key":"3_CR56","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/sj.bmt.1703652","volume":"30","author":"S Giralt","year":"2002","unstructured":"Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P, Molldrem J, Ueno NT, Donato M, Korbling M, Gajewski J, Alexanian R, Champlin R (2002) Fludarabine\/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 30:367\u2013373","journal-title":"Bone Marrow Transplant"},{"key":"3_CR57","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood.V81.12.3382.3382","volume":"81","author":"PR Greipp","year":"1993","unstructured":"Greipp PR, Lust JA, O\u2019Fallon WM, Katzmann JA, Witzig TE, Kyle RA (1993) Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 81:3382\u20133387","journal-title":"Blood"},{"key":"3_CR58","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/bbmt.2003.50002","volume":"9","author":"T Hahn","year":"2003","unstructured":"Hahn T, Wingard JR, Anderson KC, Bensinger Wl, Berenson JR, Brozeit G, Carver JR, Kyle RA, McCarthy PL Jr (2003) The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. Biol Blood Marrow Transplant 9:4\u201337","journal-title":"Biol Blood Marrow Transplant"},{"key":"3_CR59","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V91.1.3","volume":"91","author":"M Hallek","year":"1998","unstructured":"Hallek M, Bergsagel PL, Anderson KC (1998) Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91:3\u201321","journal-title":"Blood"},{"key":"3_CR60","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0268-960X(02)00043-7","volume":"16","author":"JL Harousseau","year":"2002","unstructured":"Harousseau JL, Attal M (2002) The role of stem cell transplantation in multiple myeloma. Blood Rev 16:245\u2013253","journal-title":"Blood Rev"},{"key":"3_CR61","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","volume":"50","author":"M Hjorth","year":"1993","unstructured":"Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rodjer S, Westin J (1993) Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I: a randomized study. Myeloma Group of Western Sweden. Eur J Haematol 50:95\u2013102","journal-title":"Eur J Haematol"},{"key":"3_CR62","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","volume":"121","author":"The International Myeloma Working Group","year":"2003","unstructured":"The International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121:749\u2013757","journal-title":"Br J Haematol"},{"key":"3_CR63","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/archinte.1990.00390160111022","volume":"150","author":"WJ Johnson","year":"1990","unstructured":"Johnson WJ, Kyle RA, Pineda AA, O\u2019Brien PC, Holley KE (1990) Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 150:863\u2013869","journal-title":"Arch Intern Med"},{"key":"3_CR64","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/00005792-198009000-00005","volume":"59","author":"SB Kapadia","year":"1980","unstructured":"Kapadia SB (1980) Multiple myeloma: a clinicopathologic study of 62 consecutively autopsied cases. Medicine (Baltimore) 59:380\u2013392","journal-title":"Medicine (Baltimore)"},{"key":"3_CR65","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1200\/JCO.2000.18.4.804","volume":"18","author":"R Konigsberg","year":"2000","unstructured":"Konigsberg R, Zojer N, Ackermann J, Kromer E, Kittler H, Fritz E, Kaufmann H, Nosslinger T, Riedl L, Gisslinger H, Jager U, Simonitsch I, Heinz R, Ludwig H, Huber H, Drach J (2000) Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol 18:804\u2013812","journal-title":"J Clin Oncol"},{"key":"3_CR66","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1182\/blood-2002-01-0131","volume":"100","author":"N Kroger","year":"2002","unstructured":"Kroger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T, Fehse B, Togel F, Wittkowsky G, Kuse R, Zander AR (2002) Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 100:755\u2013760","journal-title":"Blood"},{"key":"3_CR67","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1046\/j.1365-2141.2000.02318.x","volume":"111","author":"RA Kyle","year":"2000","unstructured":"Kyle RA (2000) Multiple myeloma: an Odyssey of discovery. Br J Haematol 111:1035\u20131044","journal-title":"Br J Haematol"},{"key":"3_CR68","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","volume":"302","author":"RA Kyle","year":"1980","unstructured":"Kyle RA, Greipp PR (1980) Smoldering multiple myeloma. N Engl J Med 302:1347\u20131349","journal-title":"N Engl J Med"},{"key":"3_CR69","first-page":"451","volume":"66","author":"RA Kyle","year":"1982","unstructured":"Kyle RA, Pajak TF, Henderson ES, Nawabi IU, Brunner K, Henry PH, Mclntyre OR, Holland JF (1982) Multiple myeloma resistant to melpha-lan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone. Cancer Treat Rep 66:451\u2013456","journal-title":"Cancer Treat Rep"},{"key":"3_CR70","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton U III (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346:564\u2013569","journal-title":"N Engl J Med"},{"key":"3_CR71","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR (2003) Review of 1,027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21\u201333","journal-title":"Mayo Clin Proc"},{"key":"3_CR72","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood.V93.1.300","volume":"93","author":"MQ Lacy","year":"1999","unstructured":"Lacy MQ, Donovan KA, Heimbach JK, Ahmann GJ, Lust JA (1999) Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 93:300\u2013305","journal-title":"Blood"},{"key":"3_CR73","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1046\/j.1365-2141.2000.02012.x","volume":"109","author":"JJ Lahuerta","year":"2000","unstructured":"Lahuerta JJ, Martinez-Lopez J, Serna JD, Blad\u00e9 J, Grande C, Alegre A, Vazquez L, Garcia-Larana J, Sureda A, Rubia JD, Conde E, Martinez R, Perez-Equiza K, Moraleda JM, Leon A, Besalduch J, Cabrera R, Miguel JD, Morales A, Garcia-Ruiz JC, Diaz-Mediavilla J, San-Miguel J (2000) Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 109:438\u2013446","journal-title":"Br J Haematol"},{"key":"3_CR74","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3109\/10428199409049639","volume":"13","author":"RE Lenhard","year":"1994","unstructured":"Lenhard RE, Daniels MJ, Oken MM, Glick JH, Ettinger DS, Kalish L, O\u2019Connell MJ (1994) An aggressive high dose cyclophosphamide and prednisone regimen for advanced multiple myeloma. Leuk Lymphoma 13:485\u2013489","journal-title":"Leuk Lymphoma"},{"key":"3_CR75","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1200\/JCO.2000.18.16.3031","volume":"18","author":"HM Lokhorst","year":"2000","unstructured":"Lokhorst HM, Schattenberg A, Cornelissen JJ, van Oers MH, Fibbe W, Russell I, Donk NW, Verdonck LF (2000) Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 18:3031\u20133037","journal-title":"J Clin Oncol"},{"key":"3_CR76","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1080\/028418600750063569","volume":"39","author":"H Ludwig","year":"2000","unstructured":"Ludwig H, Fritz E (2000) Interferon in multiple myeloma: summary of treatment results and clinical implications. Acta Oncol 39:815\u2013821","journal-title":"Acta Oncol"},{"key":"3_CR77","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/0140-6736(92)90004-M","volume":"339","author":"IC MacLennan","year":"1992","unstructured":"MacLennan IC, Chapman C, Dunn J, Kelly K (1992) Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults. Lancet 339:200\u2013205","journal-title":"Lancet"},{"key":"3_CR78","doi-asserted-by":"crossref","unstructured":"Maloney DG, Sandmaier BM, Mackinnon S, Shizuru JA (2002) Non-myeloablative transplantation. Hematology (Am Soc Hematol Educ Program), pp 392\u2013421","DOI":"10.1182\/asheducation-2002.1.392"},{"key":"3_CR79","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","volume":"2","author":"TJ McElwain","year":"1983","unstructured":"McElwain TJ, Powles RL (1983) High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 2:822\u2013824","journal-title":"Lancet"},{"key":"3_CR80","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.V60.4.851.851","volume":"60","author":"P McLaughlin","year":"1982","unstructured":"McLaughlin P, Alexanian R (1982) Myeloma protein kinetics following chemotherapy. Blood 60:851\u2013855","journal-title":"Blood"},{"key":"3_CR81","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/bjc.1980.329","volume":"42","author":"Medical Research Council\u2019s Working Party on Leukaemia in Adults","year":"1980","unstructured":"Medical Research Council\u2019s Working Party on Leukaemia in Adults (1980) Treatment comparisons in the third MRC myelomatosis trial. Br J Cancer 42:823\u2013830","journal-title":"Br J Cancer"},{"key":"3_CR82","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"P Moreau","year":"2002","unstructured":"Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, Sotto JJ, Guilhot F, Marit G, Doyen C, Jaubert J, Fuzibet JG, Fran\u00e7ois S, Benboubker L, Monconduit M, Voillat L, Macro M, Berthou C, Dorvaux V, Pignon B, Rio B, Matthes T, Casassus P, Caillot D, Najman N, Grosbois B, Bataille R, Harousseau JL (2002) Comparison of 200 mg\/m2 melphalan and 8 Gy total body irradiation plus 140 mg\/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du My\u00e9lome 9502 randomized trial. Blood 99:731\u2013735","journal-title":"Blood"},{"key":"3_CR83","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1136\/bmj.288.6428.1411","volume":"288","author":"MRC Working Party on Leukaemia in Adults","year":"1984","unstructured":"MRC Working Party on Leukaemia in Adults (1984) Analysis and management of renal failure in fourth MRC myelomatosis trial. Br Med J (Clin Res Ed) 288:1411\u20131416","journal-title":"Br Med J (Clin Res Ed)"},{"key":"3_CR84","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","volume":"16","author":"Myeloma Trialists\u2019 Collaborative Group","year":"1998","unstructured":"Myeloma Trialists\u2019 Collaborative Group (1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists\u2019 Collaborative Group. J Clin Oncol 16:3832\u20133842","journal-title":"J Clin Oncol"},{"key":"3_CR85","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1046\/j.1365-2141.2001.02857.x","volume":"113","author":"Myeloma Trialists\u2019 Collaborative Group","year":"2001","unstructured":"Myeloma Trialists\u2019 Collaborative Group (2001) Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 113:1020\u20131034","journal-title":"Br J Haematol"},{"key":"3_CR86","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1600-0609.1999.tb01730.x","volume":"62","author":"TM Oivanen","year":"1999","unstructured":"Oivanen TM, Kellokumpu-Lehtinen P, Koivisto AM, Koivunen E, Palva I (1999) Response level and survival after conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study. Eur J Haematol 62:109\u2013116","journal-title":"Eur J Haematol"},{"key":"3_CR87","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3109\/10428199609052427","volume":"20","author":"MM Oken","year":"1996","unstructured":"Oken MM, Kyle RA, Greipp PR, Kay NE, Tsiatis A, Gregory SA, Spiegel RJ, O\u2019Connell MJ (1996a) Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma. Leuk Lymphoma 20:447\u2013452","journal-title":"Leuk Lymphoma"},{"key":"3_CR88","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/S0002-9343(95)00043-7","volume":"100","author":"MM Oken","year":"1996","unstructured":"Oken MM, Pomeroy C, Weisdorf D, Bennett JM (1996 b) Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 100:624\u2013628","journal-title":"Am J Med"},{"key":"3_CR89","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/1097-0142(19910901)68:5<975::AID-CNCR2820680511>3.0.CO;2-O","volume":"68","author":"A Paccagnella","year":"1991","unstructured":"Paccagnella A, Chiarion-Sileni V, Soesan M, Baggio G, Bolzonella S, De Besi P, Casara D, Frizzarin M, Salvagno L, Favaretto A, Fiorentino MV (1991) Second and third responses to the same induction regimen in relapsing patients with multiple myeloma. Cancer 68:975\u2013980","journal-title":"Cancer"},{"key":"3_CR90","first-page":"399","volume":"86","author":"A Palumbo","year":"2001","unstructured":"Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C, Triolo S, Gallo E, Pileri A, Boccadoro M (2001) Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 86:399\u2013403","journal-title":"Haematologica"},{"key":"3_CR91","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/0959-8049(94)00452-B","volume":"2","author":"D Peest","year":"1995","unstructured":"Peest D, Deicher H, Coldewey R, Leo R, Bartl R, Bartels H, Braun HJ, Fett W, Fischer JT, G\u00f6bel B, Harms P, Henke R, Hoffmann L, Kreuser ED, Maier WD, Meier CR, Oertel J, Petit M, Planker M, Platzeck C, Respondek M, Sch\u00e4fer E, Schumacher K, Stennes M, Stenzinger W, Tirier C, Wagner H, Weh HJ, von Wussow P, Wysk J (1995) A comparison of polychemotherapy and melphalan\/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group. Eur J Cancer 2:146\u2013151","journal-title":"Eur J Cancer"},{"key":"3_CR92","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood.V98.3.579","volume":"98","author":"LF Porrata","year":"2001","unstructured":"Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A, Gastineau DA, Dispenzieri A, Ansell SM, Micallef IN, Geyer SM, Markovic SN (2001) Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 98:579\u2013585","journal-title":"Blood"},{"key":"3_CR93","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S0889-8588(05)70128-3","volume":"13","author":"SV Rajkumar","year":"1999","unstructured":"Rajkumar SV, Greipp PR (1999) Prognostic factors in multiple myeloma. Hematol Oncol Clin North Am 13:1295\u20131314","journal-title":"Hematol Oncol Clin North Am"},{"key":"3_CR94","doi-asserted-by":"publisher","first-page":"897","DOI":"10.4065\/75.9.897","volume":"75","author":"SV Rajkumar","year":"2000","unstructured":"Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Kyle RA, Gertz MA, Greipp PR (2000) Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 75:897\u2013901","journal-title":"Mayo Clin Proc"},{"key":"3_CR95","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/sj.leu.2402183","volume":"15","author":"SV Rajkumar","year":"2001","unstructured":"Rajkumar SV, Dispenzieri A, Fonseca R, Lacy MQ, Geyer S, Lust JA, Kyle RA, Greipp PR, Gertz MA, Witzig TE (2001) Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 15:1274\u20131276","journal-title":"Leukemia"},{"key":"3_CR96","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","volume":"20","author":"SV Rajkumar","year":"2002","unstructured":"Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, Geyer S, Iturria N, Fonseca R, Lust JA, Kyle RA, Witzig TE (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20:4319 \u2013 4323","journal-title":"J Clin Oncol"},{"key":"3_CR97","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1126\/science.276.5320.1851","volume":"276","author":"MB Rettig","year":"1997","unstructured":"Rettig MB, Ma HJ, Vescio RA, Pold M, Schiller G, Belson D, Savage A, Nishikubo C, Wu C, Fraser J, Said JW, Berenson JR (1997) Kaposi\u2019s sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 276:1851\u20131854","journal-title":"Science"},{"key":"3_CR98","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1054\/bjoc.1999.1087","volume":"82","author":"A Riccardi","year":"2000","unstructured":"Riccardi A, Mora O, Tinelli C, Valentini D, Brugnatelli S, Spanedda R, De Paoli A, Barbarano L, Di Stasi M, Giordano M, Delfini C, Nicoletti G, Bergonzi C, Rinaldi E, Piccinini L, Ascari E (2000) Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer 82:1254\u20131260","journal-title":"Br J Cancer"},{"key":"3_CR99","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","volume":"100","author":"PG Richardson","year":"2002","unstructured":"Richardson PG, Schlossman RL, Weiler E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063\u20133067","journal-title":"Blood"},{"key":"3_CR100","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J, Singhal, S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609\u20132617","journal-title":"N Engl J Med"},{"key":"3_CR101","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1001\/jama.1969.03150200094011","volume":"207","author":"SL Rivers","year":"1969","unstructured":"Rivers SL, Patno ME (1969) Cyclophosphamide vs melphalan in treatment of plasma cell myeloma. JAMA 207:1328\u20131334","journal-title":"JAMA"},{"key":"3_CR102","first-page":"377","volume":"7","author":"LS Rosen","year":"2001","unstructured":"Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen B-L, Ambros Y (2001) Zoledronic acid versus Pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7:377\u2013387","journal-title":"Cancer J"},{"key":"3_CR103","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.1990.8.9.1575","volume":"8","author":"SE Salmon","year":"1990","unstructured":"Salmon SE, Tesh D, Crowley J, Saeed S, Finley P, Milder MS, Hutchins LF, Coliman CA Jr, Bonnet JD, Cheson B, Knost JA, Samhouri A, Beckford J, Stock-Novack D (1990) Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 8:1575\u20131584","journal-title":"J Clin Oncol"},{"key":"3_CR104","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.1998.16.3.890","volume":"16","author":"SE Salmon","year":"1998","unstructured":"Salmon SE, Crowley JJ, Balcerzak SP, Roach RW, Taylor SA, Rivkin SE, Samlowski W (1998) Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 16:890\u2013896","journal-title":"J Clin Oncol"},{"key":"3_CR105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2141.1987.tb06890.x","volume":"66","author":"PJ Selby","year":"1987","unstructured":"Selby PJ, McElwain TJ, Nandi AC, Perren TJ, Powles RL, Tillyer CR, Osborne RJ, Slevin ML, Malpas JS (1987) Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 66:55\u201362","journal-title":"Br J Haematol"},{"key":"3_CR106","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1182\/blood.V98.7.2229","volume":"98","author":"NV Smadja","year":"2001","unstructured":"Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C, on behalf of the Groupe Fran\u00e7ais de Cytogenetique Hematologique (2001) Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98:2229\u20132238","journal-title":"Blood"},{"key":"3_CR107","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/archinte.1975.00330010149019","volume":"135","author":"Southwest Oncology Group study","year":"1975","unstructured":"Southwest Oncology Group study (1975) Remission maintenance therapy for multiple myeloma. Arch Intern Med 135:147\u2013152","journal-title":"Arch Intern Med"},{"key":"3_CR108","first-page":"318","volume":"13","author":"JR Sporn","year":"1986","unstructured":"Sporn JR, Mclntyre OR (1986) Chemotherapy of previously untreated multiple myeloma patients: an analysis of recent treatment results. Semin Oncol 13:318\u2013325","journal-title":"Semin Oncol"},{"key":"3_CR109","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1046\/j.1365-2141.2000.01958.x","volume":"108","author":"S Titzer","year":"2000","unstructured":"Titzer S, Christensen O, Manzke O, Tesch H, Wolf J, Emmerich B, Carsten C, Diehl V, Bohlen H (2000) Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol 108:805\u2013816","journal-title":"Br J Haematol"},{"key":"3_CR110","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/0145-2126(85)90075-X","volume":"9","author":"M Tribalto","year":"1985","unstructured":"Tribalto M, Amadori S, Cantonetti M, Franchi A, Papa G, Pileri A, Boccadoro M, Dammacco F, Vacca A, Centurioni R, Leoni P, Martelli M, Aversa F, Tonato M, Deriv L, Guarino S, Neri A, Pericolo Ridolfini F, Mandelli F (1985) Treatment of multiple myeloma: a randomized study of three different regimens. Leuk Res 9:1043\u20131049","journal-title":"Leuk Res"},{"key":"3_CR111","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","volume":"87","author":"G Tricot","year":"1996","unstructured":"Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B (1996) Graft-versus-myeloma effect: proof of principle. Blood 87:1196\u20131198","journal-title":"Blood"},{"key":"3_CR112","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","volume":"21","author":"D Weber","year":"2003","unstructured":"Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21:16\u201319","journal-title":"J Clin Oncol"},{"key":"3_CR113","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1046\/j.1365-2141.1997.1122939.x","volume":"97","author":"DM Weber","year":"1997","unstructured":"Weber DM, Dimopoulos MA, Moulopoulos LA, Delasalle KB, Smith T, Alexanian R (1997) Prognostic features of asymptomatic multiple myeloma. Br J Haematol 97:810\u2013814","journal-title":"Br J Haematol"},{"key":"3_CR114","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1182\/blood.V95.6.1925","volume":"95","author":"N Zojer","year":"2000","unstructured":"Zojer N, Konigsberg R, Ackermann J, Fritz E, Dallinger S, Kromer E, Kaufmann H, Riedl L, Gisslinger H, Schreiber S, Heinz R, Ludwig H, Huber H, Drach J (2000) Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 95:1925\u20131930","journal-title":"Blood"}],"container-title":["Hematologic Malignancies: Multiple Myeloma and Related Plasma Cell Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-662-08885-2_3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T01:01:56Z","timestamp":1596070916000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-662-08885-2_3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"ISBN":["9783642056437","9783662088852"],"references-count":114,"URL":"https:\/\/doi.org\/10.1007\/978-3-662-08885-2_3","relation":{},"subject":[],"published":{"date-parts":[[2004]]}}}